Stiff person syndrome
Objective: Two case reports of Stiff person syndrome (SPS) and SPS variant- Stiff limb syndrome. Background: Stiff person syndrome is a rare autoimmune disorder of…Safety of nelotanserin in a randomized placebo-controlled phase 2 study
Objective: To explore the safety of nelotanserin in a phase 2 study in patients with nelotanserin. Background: Nelotanserin is a highly selective and poent inverse…AMP kinase regulates ligand-gated K-ATP channels in substantia nigra dopamine neurons
Objective: To characterize the effect of AMP-activated protein kinase (AMPK) on ATP-sensitive K+ (K-ATP) channels on substantia nigra compacta (SNC) dopamine neurons in slices of…Clinical characterization of pramipexole induced edema in Parkinson’s disease (PD). Is it always the best option discontinue the treatment?
Objective: Report a patient with PD treated with irregular doses of pramipexole and extensive chronic edema in lower extremities after 8 years of treatment, taking…Fighting Freezing of gait in Parkinson’s disease: Effect of a phase-dependent tactile biofeedback
Objective: To investigate the effect of tactile biofeedback during every stance phase on freezing of gait (FoG) in Parkinson's disease (PD). Background: Accumulating evidence suggests…PD COMM Pilot: A pilot randomised controlled trial of Lee Silverman voice treatment (LSVT) versus NHS speech and language therapy versus no intervention in Parkinson’s
Objective: To evaluate the feasibility of a full scale trial on the effectiveness and cost-effectiveness of two types of speech and language therapy (SLT) for…Lovastatin protects neurite degeneration in LRRK2-G2019S parkinsonism through activating the Akt/Nrf pathway and inhibiting GSK3beta activity
Objective: To identify disease-modifying therapy for LRRK2-G2019S parkinsonism. Background: Leucine-rich repeat kinase 2 (LRRK2) is the most common genetic cause of Parkinson's disease (PD) without…The CNS moving voice program: Implementation of a dual voice and physical exercise program for Parkinson’s disease: An applicability study
Objective: To test the applicability of a rehabilitation program for people with Parkinson´s disease that combines speech and motor exercises (The CNS Moving Voice Program).…Nilotinib significantly alters CSF biomarkers and increases endogenous dopamine in open-label phase I clinical trial in Parkinson’s disease with dementia and Lewy body dementia
Objective: The objective was to determine whether Nilotinib crosses the blood brain barrier (BBB). Background: Parkinson's disease (PD) involves death of dopamine producing neurons in…Patient case reports supporting a long-term effect of sub-anesthetic ketamine infusion in reducing L-DOPA-induced dyskinesias
Objective: To evaluate possible long-term anti-dyskinetic activity of low-dose sub-anesthetic ketamine infusion from a retrospective chart review. Background: Repurposing drugs that have already been proven…
- « Previous Page
- 1
- …
- 181
- 182
- 183
- 184
- 185
- …
- 207
- Next Page »